For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.

3 April, 2007
The latest issue of Australian Prescriber addresses the potentially confusing topic of generic medicines and their possible adverse reactions.The article is written by three distinguished academics – Professor Andrew McLachlan and Professor Iqbal Ramzan from the University of Sydney, and Associate Professor Robert Milne of the University of South Australia.
Generic medicines are usually manufactured after the patent period has expired on branded medicines. “The generic product has to be proven to be bioequivalent to the branded product. This means that they produce such similar plasma concentrations of the active ingredient that their clinical effects can be expected to be the same,” the authors explain. “Generic drugs must also adhere to the strict quality standards set by the Therapeutic Goods Administration (TGA).”
“On scientific grounds there is no reason to be concerned about substituting a generic product for a branded product that is flagged as being bioequivalent,” writes Professor McLachlan.
Switching products that are not bioequivalent may lead to lower or higher blood concentrations of a drug. This may increase the risk of therapeutic failure or drug-related toxicity.
There are some medicines, such as the two brands of warfarin, which should not be substituted as they are not known to be bioequivalent.
“Although generic drugs are bioequivalent, they may have different excipients – such as diluents, binders, fillers, surfactants, lubricants, coatings and dyes,” says Professor McLachlan.
The quality and safety of all excipients are carefully reviewed by the TGA and can only be used if they are safe and non-toxic. There is evidence, though, that excipients may have an impact on patient tolerability. “The main risk is allergy or intolerance to a specific ingredient such as lactose,” he says.
“Before prescribing, it is imperative to consider the patient’s understanding of their medicines and the risk of medication misadventure. Elderly patients, those with cognitive impairment and patients taking multiple medicines for serious chronic illness are at greatest risk,” Professor McLachlan says.
ENDS
For the complete article visit the Australian Prescriber website www.australianprescriber.com. Australian Prescriber is an independent peer-reviewed journal providing critical commentary on therapeutic topics for health professionals. It is published by National Prescribing Service Limited (NPS), an independent, non-profit organisation for Quality Use of Medicines funded by the Australian Government Department of Health and Ageing.
Media enquiries
Contact us
Date published: 2007-04-03 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.